| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5681395 | Medicine - Programa de Formación Médica Continuada Acreditado | 2017 | 16 Pages |
Abstract
IECA/ARA-II, beta- blockers and aldosterone antagonists are drugs that have been shown to improve survival in HF patients. Recently, a new compound (LCZ696) that combines an ARA-II (valsartan) and a neprilysin inhibitor (sacubitril) have proven better than an IECA (enalapril) in reducing the risk of death and hospitalisation due to HF.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
C. Robles Gamboa,